REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of “Moderate Buy” by Brokerages

REGENXBIO Inc. (NASDAQ:RGNX) has earned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $33.88.

Several analysts have weighed in on the company. HC Wainwright dropped their price objective on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a report on Monday, March 17th. Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $38.00 to $14.00 in a research note on Tuesday, February 11th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Finally, Chardan Capital reissued a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday.

Institutional Trading of REGENXBIO

Large investors have recently made changes to their positions in the company. FMR LLC lifted its holdings in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,656 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of REGENXBIO by 9.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 1,982 shares during the period. Teacher Retirement System of Texas raised its position in shares of REGENXBIO by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 2,088 shares during the period. DnB Asset Management AS lifted its holdings in shares of REGENXBIO by 20.1% during the 4th quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 2,434 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the period. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Price Performance

RGNX stock opened at $8.24 on Friday. The company has a 50 day moving average price of $7.30 and a 200 day moving average price of $8.90. REGENXBIO has a fifty-two week low of $5.62 and a fifty-two week high of $22.84. The stock has a market capitalization of $408.25 million, a PE ratio of -1.64 and a beta of 1.35.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million. As a group, equities analysts expect that REGENXBIO will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.